This is particularly important because currently the application of ERBB2-targeting drugs is limited to patients whose tumours express high levels of the ERBB2 protein or show amplification of the ERBB2 gene (Hynes and Lane, 2005). This evidence concerns the gene ERBB2 and neoplasm.